Efatec
- ENG
- မြန်မာ
COMPOSITION
Each film coated tablet contains:
EFAVIRENZ 200MG/ 600MG
DESCRIPTION
Efavirenz is a non-nucleoside reverse transcriptase (RT) inhibitor of human immunodeficiency virus type 1 (HIV-1).
INDICATIONS
Efavirenz in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection.
CONTRAINDICATIONS
EFATEC is contraindicated in patients with clinically significant hypersensitivity to any of its components.
DOSAGE AND ADMINISTRTION
Adults: The recommended dosage of EFATEC orally, in combination with a protease inhibitor and or nucleoside analogue reverse transcriptase inhibitors (NRTIs). EFATEC may be taken with or without food; however, a high fat meal may increase the absorption of EFATEC and should be avoided.
USE IN PREGNANCY AND LACTATION
There are no adequate and well-controlled studies in pregnant women. Efavirenz should be used during pregnancy only if the potential benefits justifies the potential risk to the fetus, such as in pregnant women without other therapeutic options.
The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV infections.
DRUG INTERACTIONS
Drugs which induce C.P.A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations. Drug interactions with efavirenz are summarized below.
| Drugs That Should Not Be Coadministered With Efavirenz | |
| Drug Class | Drugs Within Class Not To Be Coadministered With Efavirenz |
| Antihistamines | astemizole |
| Benzodiazepines | midazolam, triazolam |
| GI Motility Agents | cisapride |
| Drugs That Require A Dose Adjustment When Coadministered With Efavirenz | |
| Drug Class | Drug Within Class Requiring Dose Increase |
| Anti-HIV Protease Inhibitor | indinavir (increase dose from 800mg to 1000 mg every 8 hours) |
| Other Potentially Clinically Significant Drug Interactions With Efavirenz | |
| Anticoagulants: Warfarin | Plasma concentrations and effects potentially increased or decreased by Efavirenz |
| Anti-HIV Protease Inhibitor: Saquinavir | Plasma concentrations decreased by Efavirenz should not be used as sole protease inhibitor in combination with Efavirenz |
| Antimycobacterial Agents: Clarithromycin | Plasma concentrations decreased by Efavirenzclinical significance unknown |
| Rifabutin | Effects unknow |
| Rifampin | Decreases efavirenz plasma concentrations; clinical significance unknown |
| Estrogens: Ethinyl Estradiol | Plasma concentrations increased by Efavirenz clinical significance unknown |
PRESENTATION
PACK OF 3X10’S